Department of Pharmacology and Toxicology, State University of New York, Buffalo, New York 14214-3000, USA.
Br J Pharmacol. 2010 Jan 1;159(2):405-18. doi: 10.1111/j.1476-5381.2009.00539.x. Epub 2009 Dec 15.
Selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex) were developed as NSAIDs with reduced gastric side effects. Celecoxib has now been shown to affect cellular physiology via an unexpected, COX-independent, pathway - by inhibiting K(v)2.1 and other ion channels. In this study, we investigated the mechanism of the action of celecoxib on K(v)2.1 channels.
The mode of action of celecoxib on rat K(v)2.1 channels was studied by whole-cell patch-clamping to record currents from channels expressed in HEK-293 cells.
Celecoxib reduced current through K(v)2.1 channels when applied from the extracellular side. At low concentrations (<or=3 microM), celecoxib accelerated kinetics of activation, deactivation and inactivation. Recovery of rat K(v)2.1 channels from inactivation could be characterized by two components, with celecoxib selectively accelerating the slow component of recovery at <or=10 microM. At >3 microM, celecoxib led to closed-channel block with relative slowing of activation. At 30 microM, it additionally induced open-channel block that manifested in use-dependent inhibition and slower recovery from inactivation.
Celecoxib reduced current through K(v)2.1 channels by modifying gating and inducing closed- and open-channel block, with the three effects manifesting at different concentrations. These data will help to elucidate the mechanisms of action of this widely prescribed drug on ion channels and those underlying its neurological, cardiovascular and other effects.
选择性环氧化酶-2(COX-2)抑制剂,如罗非昔布(万络)和塞来昔布(西乐葆),作为具有减少胃副作用的 NSAIDs 而被开发。现在已经表明,塞来昔布通过抑制 K(v)2.1 和其他离子通道,通过一种意想不到的、非 COX 依赖性的途径影响细胞生理学。在这项研究中,我们研究了塞来昔布对 K(v)2.1 通道作用的机制。
通过全细胞膜片钳记录在 HEK-293 细胞中表达的通道电流,研究塞来昔布对大鼠 K(v)2.1 通道的作用方式。
当从细胞外应用时,塞来昔布减少了 K(v)2.1 通道的电流。在低浓度(<或=3 microM)下,塞来昔布加速了激活、失活和失活的动力学。大鼠 K(v)2.1 通道从失活中恢复的过程可以用两个分量来描述,在<或=10 microM 时,塞来昔布选择性地加速了慢分量的恢复。在>3 microM 时,塞来昔布导致闭孔阻断,激活相对减慢。在 30 microM 时,它还诱导了开孔阻断,表现为使用依赖性抑制和从失活中恢复较慢。
塞来昔布通过改变门控并诱导闭孔和开孔阻断来减少 K(v)2.1 通道的电流,这三种效应在不同的浓度下表现出来。这些数据将有助于阐明这种广泛应用的药物对离子通道的作用机制及其对神经、心血管和其他作用的基础。